Related Experiment Videos
Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention
1Department of Medicine, University of Minnesota Medical School, Minneapolis 55455.
Insights
Congestive heart failure involves impaired heart muscle function and remodeling. Vasodilator drugs help reduce symptoms by improving blood flow, but new strategies are needed to address underlying cellular changes for long-term benefits.
Area of Science:
- Cardiology
- Heart Failure Pathophysiology
- Pharmacology
Background:
- Congestive heart failure (CHF) stems from myocardial cell dysfunction, leading to reduced ventricular performance, exercise intolerance, and arrhythmias.
- Left ventricular remodeling, including cellular changes and shape alterations post-myocardial infarction, significantly impacts CHF progression.
- Vascular dysfunction, characterized by arteriolar constriction and reduced arterial compliance, is a hallmark of CHF, influenced by multiple regulatory factors.
Purpose of the Study:
- To explore the mechanisms underlying myocardial and vascular remodeling in heart failure.
- To investigate the role of pharmacologic interventions in preventing adverse remodeling.
- To identify critical cellular and subcellular targets for innovative therapeutic strategies in CHF.
Main Methods:
- Review of current understanding of myocardial and vascular pathophysiology in heart failure.
- Analysis of the effects of vasodilator drugs on cardiac performance and vascular tone.
- Exploration of emerging therapeutic approaches targeting cellular remodeling processes.
Main Results:
- Vasodilators effectively reduce impedance, afterload, and preload, improving cardiac function and relieving CHF symptoms.
- Structural changes like hypertrophy and remodeling contribute to vascular resistance and capacitance alterations.
- Pharmacologic interventions aimed at preventing remodeling are under investigation, though mechanisms remain poorly defined.
Conclusions:
- Improving left ventricular function through interventions like vasodilators is critical for symptom relief in heart failure.
- Long-term management of CHF necessitates targeting myocardial and peripheral vascular remodeling processes.
- Further research into cellular and subcellular mechanisms is essential for developing novel therapeutic strategies for progressive heart failure.
Abstract:
Congestive heart failure is a complex clinical syndrome that has its basis in an abnormality of myocardial cell function resulting in impaired ventricular performance, exercise intolerance, and ventricular arrhythmias. The functional defect in myocardial performance may be related to alterations in receptor function, in regulatory proteins, or in biochemical mechanisms. Remodeling of the left ventricle has been observed to play an important role in the natural course of heart failure. The complex interplay between cellular elongation, reactive hypertrophy, and the influence of the change from ellipsoid to spheroidal shape of the left ventricle after acute myocardial infarction are just beginning to be understood. Prevention of this remodeling effect by pharmacologic intervention is being widely explored, although the mechanisms are poorly defined. Impedance to left ventricular ejection is also an important determinant of cardiac performance in heart failure. Constriction of arteriolar resistance vessels and reduction in compliance of arterial conductance vessels is a common manifestation of heart failure and may be under the influence of neural, hormonal, endothelial, and local regulatory factors. Increased tone of venous capacitance vessels contributes to a shift of blood centrally and to an increase in ventricular preload. Vasodilator drugs by relaxing the arterial, arteriolar, and venous vasculature result in a reduction in impedance and left ventricular afterload and a decrease in cardiac filling pressure and preload. Structural changes of hypertrophy and remodeling apparently contribute to the changes in resistance, compliance, and capacitance in the vasculature. Treatment of heart failure is aimed at relieving symptoms and prolonging life. Interventions to improve left ventricular function are critical to symptom relief. Vasodilators have been most effective for this purpose, and new positive inotropic drugs are being tested for efficacy. Long-term benefit may require interference with the myocardial and peripheral vascular remodeling processes that lead to progressive depression of ventricular performance. New insights into the cellular and subcellular mechanisms of this progression are critical to the development of innovative therapeutic strategies.